<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198676</url>
  </required_header>
  <id_info>
    <org_study_id>PrEP-001-104</org_study_id>
    <nct_id>NCT03198676</nct_id>
  </id_info>
  <brief_title>A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production</brief_title>
  <official_title>A Single Centre, Partially Blinded, Randomised Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prep Biopharm Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prep Biopharm Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety study to compare the effect of two different formulations of PrEP-001 nasal powder&#xD;
      when dosed in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single centre, randomised, partially blinded placebo-controlled repeat dose study in&#xD;
      healthy male subjects to compare the effect of two different formulations of PrEP-001 nasal&#xD;
      powder on nasal mucosal and serum cytokine profiles when dosed for up to five days in health&#xD;
      subjects and provide additional safety and tolerability information on active PrEP-001 nasal&#xD;
      powder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">May 24, 2017</completion_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomised partially blinded, partially placebo controlled, repeat dose</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in baseline in nasal mucosal secretions and serum cytokine concentrations</measure>
    <time_frame>5 days</time_frame>
    <description>Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with 2 different formulations of PrEP 001 Nasal Powder (ie 6.4 mg Formulation B vs 6.4 mg Formulation A)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline in nasal mucosal secretions and serum cytokine concentrations</measure>
    <time_frame>5 days</time_frame>
    <description>Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with PrEP 001 Nasal Powder 6.4 mg Formulation B and matching placebo Formulation B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline in nasal mucosal secretions and serum cytokine concentrations</measure>
    <time_frame>5 days</time_frame>
    <description>Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with PrEP-001 Nasal Powder (3.2 mg and 6.4 mg Formulation B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety parameters</measure>
    <time_frame>5 days</time_frame>
    <description>Assessment of the following safety variables: physical examination, safety laboratory tests, vital signs, ECGs and AEs (Formulation B vs Formulation A)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>A - PrEP-001 6.4 mg - 0.8 mg/spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - PrEP-001 6.4 mg - 1.6 mg/spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - PrEP-001 3.2 mg - 1.6 mg/spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PrEP-001 Placebo Nasal Powder (matching Formulation B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP-001 6.4 mg</intervention_name>
    <description>6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device</description>
    <arm_group_label>A - PrEP-001 6.4 mg - 0.8 mg/spray</arm_group_label>
    <other_name>Poly-IC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP-001 6.4 mg</intervention_name>
    <description>6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device</description>
    <arm_group_label>B - PrEP-001 6.4 mg - 1.6 mg/spray</arm_group_label>
    <other_name>Poly-IC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP-001 3.2 mg</intervention_name>
    <description>3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device</description>
    <arm_group_label>C - PrEP-001 3.2 mg - 1.6 mg/spray</arm_group_label>
    <other_name>Poly-IC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device</description>
    <arm_group_label>D - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males&#xD;
&#xD;
          -  Aged 18 to 65 years&#xD;
&#xD;
          -  A body weight of &gt;50 kg and body mass index .18.0 to &lt;32.0 kg/m2&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  Must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within the previous 3&#xD;
             months&#xD;
&#xD;
          -  Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          -  Subjects who have previously been enrolled in this study&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, 25 mL of 40%&#xD;
             spirit or a 125 mL glass of wine)&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             positive urine cotinine test at screening and admission&#xD;
&#xD;
          -  Current smokers of e-cigarettes and nicotine replacement products and those who have&#xD;
             smoked these products within the last 12 months&#xD;
&#xD;
          -  Subject who have significant history of any tobacco use at any time (total ≥10 pack&#xD;
             years history)&#xD;
&#xD;
          -  Subjects who do not have suitable veins for multiple venepunctures as assessed by the&#xD;
             investigator at screening&#xD;
&#xD;
          -  Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis&#xD;
             as judged by the investigator (laboratory parameters are listed in Appendix 1)&#xD;
&#xD;
          -  Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1)&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, or psychiatric disorder, as judged by the investigator&#xD;
&#xD;
          -  Any chronic medical condition that could significantly reduce the ability of the&#xD;
             subject to participate in the study or pose a safety concern eg unstable angina,&#xD;
             uncontrolled diabetes mellitus, anaemia&#xD;
&#xD;
          -  Any concurrent serious illness (eg diagnosis of severe depression, pulmonary&#xD;
             hypertension, history of malignancy) that may interfere with a subject completing the&#xD;
             study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of&#xD;
             recurrence is also an exclusion&#xD;
&#xD;
          -  Any finding in the medical history review, physical examination (including nasal exam&#xD;
             with nasal speculae), screening investigations, that in the opinion of the&#xD;
             investigator would compromise the subject's ability to safely complete the study&#xD;
&#xD;
          -  Has experienced upper or lower respiratory infection (viral, fungal or bacterial) that&#xD;
             resolved less than 4 weeks before Day 1&#xD;
&#xD;
          -  Has required antibiotic treatment for a lower respiratory tract infection in the 3&#xD;
             months prior to the study&#xD;
&#xD;
          -  Subjects with a significant nasal condition eg Wegener's granulomatosis, that could&#xD;
             interfere with study assessments&#xD;
&#xD;
          -  Any significant abnormality altering the anatomy of the nose or nasopharynx on&#xD;
             examination&#xD;
&#xD;
          -  Any nasal or sinus surgery within 6 months of Day 1&#xD;
&#xD;
          -  Any clinically significant history of epistaxis (nosebleeds) within the last 12 months&#xD;
             and/or history of being hospitalised due to epistaxis on any previous occasion&#xD;
&#xD;
          -  History or evidence of autoimmune disease or known immunodeficiency of any cause -&#xD;
             with the exception of atopic eczema/atopic dermatitis. Subjects with clinically mild&#xD;
             atopic eczema/atopic dermatitis may be included at the Investigator's discretion (eg&#xD;
             if there is no regular use of topical steroids, no eczema in cubital fossa)&#xD;
&#xD;
          -  Subjects with known history of Immunosuppression or known chronic viral infection&#xD;
&#xD;
          -  Has active seasonal or perennial nasal/pharyngeal allergies at screening visit; or&#xD;
             anticipates to have such symptoms during the study duration; or has had symptoms in&#xD;
             the 4 weeks prior to Day 1&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment (including&#xD;
             food or drug allergy), as judged by the investigator&#xD;
&#xD;
          -  Known allergy or adverse reaction history to formulation components&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood within the previous 3 months&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP&#xD;
             administration (see Section 11.4). Exceptions may apply on a case by case basis, if&#xD;
             considered not to interfere with the objectives of the study, as agreed by the PI and&#xD;
             sponsor's medical monitor&#xD;
&#xD;
          -  Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Litza McKenzie, MBChB BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 19, 2018</submitted>
    <returned>February 8, 2019</returned>
    <submitted>June 18, 2021</submitted>
    <returned>July 9, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

